Pfizer PFE
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 95th percentile, 5-year average -13.6x
#2391 of 2972 stocks by PE (1 = cheapest)
Above its usual level · 66th percentile, 5-year average 2.2x
#3053 of 5311 stocks by PB (1 = cheapest)
Above its usual level · 72nd percentile, 5-year average 2.7x
#2954 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.04 | – | 2.18 | 66% (pricier than usual) | #3053 of 5311 (1 = cheapest) |
| PE | 40.16 | 16.38 | -13.56 | 95% (pricier than usual) | #2391 of 2972 (1 = cheapest) |
| PS | 2.73 | 2.84 | 2.66 | 72% (pricier than usual) | #2954 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on PFE.
Sign in to join the discussion.